GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Capex-to-Operating-Income

Jafron Biomedical Co (SZSE:300529) Capex-to-Operating-Income : 0.28 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Jafron Biomedical Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-95.87 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥345.65 Mil.

Hence, Jafron Biomedical Co's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.28.


Jafron Biomedical Co Capex-to-Operating-Income Historical Data

The historical data trend for Jafron Biomedical Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Capex-to-Operating-Income Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.35 0.39 0.47 0.47

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.43 0.17 3.38 0.28

Competitive Comparison of Jafron Biomedical Co's Capex-to-Operating-Income

For the Medical Devices subindustry, Jafron Biomedical Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jafron Biomedical Co's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jafron Biomedical Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Jafron Biomedical Co's Capex-to-Operating-Income falls into.



Jafron Biomedical Co Capex-to-Operating-Income Calculation

Jafron Biomedical Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-247.253) / 523.157
=0.47

Jafron Biomedical Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-95.865) / 345.648
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jafron Biomedical Co  (SZSE:300529) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Jafron Biomedical Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines